Osiris Therapeutics Reports Record Fourth Quarter and Full Year 2007 (Www.OSIR.org.in)
Phramalive.com - COLUMBIA, Md.–(BUSINESS WIRE)–Feb. 28, 2008 - Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and
Source: www.pharmalive.com
Osiris stock climbs on bioterror contract win
Baltimore Business Journal - OSIR) said late Thursday it had been awarded a contract from the Department of Defense for Prochymal, a drug it is developing from adult stem cells for bone marrow transplants and to treat Crohn’s disease, an autoimmune disorder. The drug has also
Source: baltimore.bizjournals.com
Osiris gets US contract for radiation treatment
Reuters - NEW YORK, Jan 3 (Reuters) - Osiris Therapeutics Inc (OSIR.O: Quote , Profile , Research ) said on Thursday it will receive $4.2 million to develop a treatment for radiation exposure as part of a U.S. government contract that could eventually be worth
Source: www.reuters.com
Barrick’s Golden Opportunity
BusinessWeek - The $224 million contract went instead to a rival, Osiris Therapeutics ( OSIR ). CBLI’s stock plunged from 8 to 3.31 on Jan. 4. It has since risen to 4.46 as CEO Michael Fonstein assured investors that he is still “very optimistic” about Protectan’s
Source: www.businessweek.com
Osiris Therapeutics Strengthens Management Team
Forbes - Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today the addition Dr
Source: www.forbes.com